Insights into the treatment of infliximab and vedolizumab in positive PR3-ANCA patients with moderately to severely active ulcerative colitis: multicenter real-world evidence.

ABSTRACT:

SUBMITTER: Yu Q 

PROVIDER: S-EPMC12751131 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature